TransMedics Q4 revenue rises 32%, beats expectations

TransMedics

24/02/2026 21:29

Overview

Medical technology firm's Q4 revenue rose 32%, beating analyst expectations

Net income for Q4 increased significantly, aided by a one-time tax benefit

Outlook

TransMedics expects 2026 revenue between $727 mln and $757 mln, a 20%-25% growth

Result Drivers

OCS UTILIZATION - Increased use of the Organ Care System, especially in liver and heart transplants, drove Q4 revenue growth

AVIATION EXPANSION - Expansion of aviation fleet contributed to increased service revenue

TAX BENEFIT - Net income boosted by a one-time tax benefit from deferred tax asset valuation allowance release

Company press release: ID:nPn8V4jM6a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$160.80 mln
$155.72 mln (10 Analysts)
Q4 EPS
$2.62
Q4 Net Income
$105.40 mln
Q4 Gross Margin
58.00%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Transmedics Group Inc is $149.00, about 10.7% above its February 23 closing price of $134.65

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)